Akero Therapeutics, Inc

Single-Patient EA Policies/Criteria Although Akero retains sole discretion in deciding whether to grant an expanded access request, the following criteria will guide evaluation of requests: • The condition or disease being studied is serious or life-threatening and there are no available alternative treatments; • The patient is not eligible for an ongoing or planned Akero-sponsored clinical trial; • There must be sufficient clinical data to identify an appropriate dose for the proposed use; • The potential benefit to the patient clearly outweighs the collective potential risks; • There must be adequate supply of the investigational product to meet the needs of the expanded access program without impacting the company’s clinical trials; • The patient meets any other relevant medical criteria for expanded access to the investigational product, as determined by Akero. https://akerotx.com/clinical-trials/ Available Therapies via Single-Patient EA Efruxifermin (EFX) for the treatment of nonalcoholic steatohepatitis (NASH)